

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/131025 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) *A61K 47/68* (2017.01)
C07K 16/28 (2006.01) *C07K 16/30* (2006.01)
A61P 35/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2024/140838

(22) International Filing Date:

20 December 2024 (20.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/140633

21 December 2023 (21.12.2023) CN

(71) Applicant: **LANOVA MEDICINES DEVELOPMENT
CO., LTD.** [CN/CN]; 999 Cailun Road, Building 1, Floor
5, Pudong New Area, Shanghai 201203 (CN).

(72) Inventors: **LI, Runsheng**; 999 Cailun Road, Building
1, Floor 5, Pudong New Area, Shanghai 201203 (CN).
HUANG, Wentao; 999 Cailun Road, Building 1, Floor 5,
Pudong New Area, Shanghai 201203 (CN). **ZANG, Ying
Qin**; 999 Cailun Road, Building 1, Floor 5, Pudong New
Area, Shanghai 201203 (CN).

(74) Agent: **SINO-CREATIVITY INTELLECTUAL PROP-
ERTY LAW FIRM**; Room 23A03, Block 4, the Place
Tower, No. 9 Guanghai Road, Chaoyang District, Beijing
100020 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: CONJUGATES OF ANTI-SLC34A2 ANTIBODY AND USES THEREOF

(57) Abstract: Provided herein are antibody-drug conjugates of anti-SLC34A2. These ADCs are capable of inhibiting the proliferation of the NaPi2b expressing cells. Also provided herein are the uses and methods of these ADCs in treating cancers.

WO 2025/131025 A1